N,N-diethyl-glycine tert-butylamide | 99178-32-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N-diethyl-glycine tert-butylamide
• 英文别名: N,N-Diaethyl-glycin-tert-butylamid；N-tert-butyl-2-(diethylamino)acetamide
• CAS: 99178-32-2
• 化学式: C₁₀H₂₂N₂O
• mdl: MFCD24388990
• 分子量: 186.297
• InChiKey: LVJORTLWCIKPPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异丁烯 、 N,N-二乙基氰乙酰胺 在 硫酸 作用下， 生成 N,N-diethyl-glycine tert-butylamide
  参考文献：
  名称：

  Malen; Boissier, Bulletin de la Societe Chimique de France, 1956, p. 923,925

  摘要：

  DOI：

文献信息

• KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
  申请人：AMGEN INC.

  公开号：US20180177767A1

  公开（公告）日：2018-06-28

  Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  本文提供了KRAS G12C抑制剂，其组成，以及使用方法。这些抑制剂对治疗多种疾病有用，包括胰腺癌、结直肠癌和肺癌。
• DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
  申请人：Molteni Valentina

  公开号：US20080139559A1

  公开（公告）日：2008-06-12

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了包含二芳胺结构特征的化合物。还描述了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的药物组合物和药物。还描述了使用这种化合物、药物组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理和/或症状性疾病或状况的方法。
• Kinase inhibitors
  申请人：Spada Lon T.

  公开号：US20090286773A1

  公开（公告）日：2009-11-19

  The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

  本发明涉及药物输送系统，包括眼部植入物，其中包括有机分子，能够调节酪氨酸激酶信号转导，以调节、调节和/或抑制异常细胞增殖，与聚合物结合，该聚合物用于控制、修改、调节和/或减缓治疗成分进入放置该复合物的眼部环境中的释放。
• KRAS G12C inhibitors and methods of using the same
  申请人：Amgen Inc.

  公开号：US11053226B2

  公开（公告）日：2021-07-06

  Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  本文提供了 KRAS G12C 抑制剂、其组合物以及使用方法。这些抑制剂可用于治疗多种疾病，包括胰腺癌、结直肠癌和肺癌。
• PSEUDOBASE BENZO[C]PHENANTHRIDINES WITH IMPROVED EFFICACY, STABILITY, AND SAFETY
  申请人：Shaw Kenneth

  公开号：US20080076781A1

  公开（公告）日：2008-03-27

  Pseudobase benzo[c]phenanthridines and the pharmaceutically acceptable salts thereof of Formula I are provided herein. The variables R, R 1 , R 2 , R 3 , and R 4 are defined herein. Certain pseudobase benzo[c]phenanthridines provided herein act as prodrugs, targeting the parent benzo[c]phenanthridinium alkaloid to hydrophilic or hydrophobic regions in the body. Pharmaceutical compositions comprising a pseudobase benzo[c]phenanthridine and a carrier, excipient, or diluent are provided herein. Methods of treating or preventing microbial, fungal and or viral infections and methods of treating diseases and disorders responsive to protein kinase C modulation, topoisomerase I, and/or topoisomerase II modulation are also provided.